{"success":true,"data":{"pressRelease":{"id":"176353","rtpr_id":"nPre7x24ja-20261022","ticker":"INEG","exchange":"NSE India","all_tickers":["INEG"],"title":"Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization","author":"PR Newswire","published_at":"2026-10-22T05:30:00.617Z","article_body":"Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology\nLeadership Recognition for AI-Powered Pharma Commercialization\nPR Newswire\n\nSAN ANTONIO, Oct. 22, 2026\n\nIndegene is recognized for combining domain-led AI, knowledge orchestration,\nand integrated execution to transform pharmaceutical commercialization\nworkflows.\n\nSAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=117094565&u=https%3A%2F%2Fwww.frost.com%2F&a=Frost+%26+Sullivan) is\npleased to announce that Indegene\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=4089867520&u=https%3A%2F%2Fwww.indegene.com%2F&a=Indegene) has\nreceived the 2026 Global Enabling Technology Leadership Recognition in pharma\nAI-powered commercialization services for its outstanding achievements in\nAI-powered commercialization, workflow transformation, and customer value\ncreation. The recognition highlights Indegene's leadership in helping\npharmaceutical organizations modernize complex commercialization processes\nthrough domain expertise, technology, data, and execution support.\n\nFrost & Sullivan evaluates companies through a rigorous benchmarking process\nacross two core dimensions: strategy effectiveness and strategy execution.\nIndegene excelled in both, demonstrating its ability to align its AI strategy\nwith the evolving needs of the pharmaceutical industry while executing at\nscale across commercial, medical, regulatory, safety, analytics, content, and\nfield engagement workflows.\n\n\"Indegene is redefining AI-powered pharmaceutical commercialization by\nbringing together model-agnostic technology, deep life sciences expertise,\nknowledge orchestration, and process reengineering. Its approach moves beyond\nisolated automation to create governed, connected workflows that can deliver\ngreater speed, consistency, and reliability across the commercialization value\nchain,\" said Surbhi Gupta, Industry Principal at Frost & Sullivan.\n\nGuided by a long-term growth strategy focused on integrating life sciences\nexpertise, technology, data, consulting, and execution, Indegene has\ndemonstrated its ability to adapt to a rapidly evolving AI landscape. Its\nPharma Operating System (OS) connects business decisions, workflow execution,\nand intelligence across the enterprise, helping pharmaceutical organizations\nreplace fragmented processes with integrated and adaptive operating models.\n\nInnovation remains central to Indegene's approach. Its pharma AI-powered\ncommercialization services combine generative AI, data, in-house technology\nplatforms, workflow integration, consulting, and execution support to help\nclients plan, create, review, deploy, and optimize commercial and medical\ncontent. Its Cortex life sciences-native reasoning engine enables subject\nmatter experts to codify specialized knowledge, create validated knowledge\ngraphs, and guide AI-enabled workflows across applications including\nregulatory authoring, medical writing, creative adaptation, and\nmedical-legal-regulatory review.\n\n\"Frost & Sullivan's recognition reinforces our belief that the next wave of\nvalue creation will come from connecting intelligence, decisions, and\nexecution across the enterprise. AI's true potential is realized when it is\nembedded into how organizations operate, not simply how they analyze\ninformation. At Indegene, we help life sciences companies turn knowledge into\naction, enabling smarter decisions, faster execution, and measurable business\noutcomes at scale. Our goal is to help clients build operating advantages that\nstrengthen over time and create lasting differentiation in an AI-driven\nmarket,\" said Vivek Ghai, EVP, Enterprise Commercial Solutions at Indegene.\n\nIndegene's commitment to customer experience strengthens its position in the\nmarket. By connecting strategy, data, content, execution, and measurable\noutcomes, the company helps pharmaceutical organizations reduce fragmented\nhandoffs and improve commercialization efficiency. Its platform-agnostic\napproach allows customers to work in existing technology environments,\npreferred models, cloud relationships, security requirements, and governance\nstructures, reducing adoption friction while protecting existing technology\ninvestments.\n\nIts data-driven commercialization capabilities support precision marketing,\nnext-best-action journeys, healthcare professional targeting, field force\noptimization, channel selection, content frequency planning, and marketing\nspend optimization. By connecting digital engagement, field interaction,\ncustomer relationship management, claims, affinity, and prescribing signals,\nIndegene enables more intelligent omnichannel execution and more measurable\ncommercial decision-making.\n\nFrost & Sullivan commends Indegene for establishing a standard in competitive\nstrategy, technology-enabled execution, and market responsiveness. The\ncompany's domain-led approach to AI, knowledge orchestration capabilities, and\nfocus on transparent customer value are shaping the future of pharmaceutical\ncommercialization and enabling organizations to scale AI transformation with\ngreater confidence and accountability.\n\nEach year, Frost & Sullivan presents the Enabling Technology Leadership\nRecognition to a company that demonstrates outstanding strategy development\nand implementation, resulting in measurable improvements in customer value,\ncompetitive positioning, and market impact. The recognition highlights\nforward-thinking organizations that are reshaping their industries through\ninnovation and growth excellence.\n\nFor more details, read Frost & Sullivan's analysis of Indegene's capabilities.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=452544481&u=https%3A%2F%2Fwww.frost.com%2Fwp-content%2Fuploads%2F2026%2F10%2FIndegene_Writeup.pdf&a=Indegene%27s+capabilities.)\n\nFrost & Sullivan Best Practices Recognition\nFrost & Sullivan's Best Practices Recognitions honor companies across regional\nand global markets that exhibit exceptional achievement and consistent\nexcellence in areas such as leadership, technological innovation, customer\nexperience, and strategic product development. Each recognition is the result\nof a rigorous analytical process in which Frost & Sullivan industry experts\nbenchmark performance through comprehensive interviews, deep-dive analysis,\nand extensive secondary research. The goal is to identify true best-in-class\norganizations that are driving transformative growth and setting new industry\nstandards.\nContact us: Start the discussion\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=2942711919&u=https%3A%2F%2Fww2.frost.com%2Fcontact-us%2F&a=Contact+us%3A+Start+the+discussion).\n\nContact:\nTarini Singh\nE: Tarini.Singh@frost.com \n\nAbout Indegene\nIndegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner\nto the life sciences industry, orchestrating commercial, medical, R&D, and\nsafety operations across the product lifecycle. Trusted by the world's top 20\nbiopharma companies, Indegene helps run complex, highly regulated workflows at\nglobal scale.\n\nIndegene combines deep life sciences expertise with AI-embedded platforms and\ngoverned operating models to improve speed, consistency, and compliance across\nmission-critical operations. By integrating technology into how work is\nexecuted and scaled, Indegene enables life sciences organizations to deliver\nmeasurable outcomes in regulated environments.\n\nFor more information, visit www.indegene.com.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/indegene-receives-frost--sullivans-2026-global-enabling-technology-leadership-recognition-for-ai-powered-pharma-commercialization-302910484.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPre7x24ja-20261022","title":"Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization","author":"PR Newswire","ticker":"INEG","created":"2026-10-22T05:30:00.617Z","tickers":["INEG"],"exchange":"NSE India","article_body":"Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology\nLeadership Recognition for AI-Powered Pharma Commercialization\nPR Newswire\n\nSAN ANTONIO, Oct. 22, 2026\n\nIndegene is recognized for combining domain-led AI, knowledge orchestration,\nand integrated execution to transform pharmaceutical commercialization\nworkflows.\n\nSAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=117094565&u=https%3A%2F%2Fwww.frost.com%2F&a=Frost+%26+Sullivan) is\npleased to announce that Indegene\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=4089867520&u=https%3A%2F%2Fwww.indegene.com%2F&a=Indegene) has\nreceived the 2026 Global Enabling Technology Leadership Recognition in pharma\nAI-powered commercialization services for its outstanding achievements in\nAI-powered commercialization, workflow transformation, and customer value\ncreation. The recognition highlights Indegene's leadership in helping\npharmaceutical organizations modernize complex commercialization processes\nthrough domain expertise, technology, data, and execution support.\n\nFrost & Sullivan evaluates companies through a rigorous benchmarking process\nacross two core dimensions: strategy effectiveness and strategy execution.\nIndegene excelled in both, demonstrating its ability to align its AI strategy\nwith the evolving needs of the pharmaceutical industry while executing at\nscale across commercial, medical, regulatory, safety, analytics, content, and\nfield engagement workflows.\n\n\"Indegene is redefining AI-powered pharmaceutical commercialization by\nbringing together model-agnostic technology, deep life sciences expertise,\nknowledge orchestration, and process reengineering. Its approach moves beyond\nisolated automation to create governed, connected workflows that can deliver\ngreater speed, consistency, and reliability across the commercialization value\nchain,\" said Surbhi Gupta, Industry Principal at Frost & Sullivan.\n\nGuided by a long-term growth strategy focused on integrating life sciences\nexpertise, technology, data, consulting, and execution, Indegene has\ndemonstrated its ability to adapt to a rapidly evolving AI landscape. Its\nPharma Operating System (OS) connects business decisions, workflow execution,\nand intelligence across the enterprise, helping pharmaceutical organizations\nreplace fragmented processes with integrated and adaptive operating models.\n\nInnovation remains central to Indegene's approach. Its pharma AI-powered\ncommercialization services combine generative AI, data, in-house technology\nplatforms, workflow integration, consulting, and execution support to help\nclients plan, create, review, deploy, and optimize commercial and medical\ncontent. Its Cortex life sciences-native reasoning engine enables subject\nmatter experts to codify specialized knowledge, create validated knowledge\ngraphs, and guide AI-enabled workflows across applications including\nregulatory authoring, medical writing, creative adaptation, and\nmedical-legal-regulatory review.\n\n\"Frost & Sullivan's recognition reinforces our belief that the next wave of\nvalue creation will come from connecting intelligence, decisions, and\nexecution across the enterprise. AI's true potential is realized when it is\nembedded into how organizations operate, not simply how they analyze\ninformation. At Indegene, we help life sciences companies turn knowledge into\naction, enabling smarter decisions, faster execution, and measurable business\noutcomes at scale. Our goal is to help clients build operating advantages that\nstrengthen over time and create lasting differentiation in an AI-driven\nmarket,\" said Vivek Ghai, EVP, Enterprise Commercial Solutions at Indegene.\n\nIndegene's commitment to customer experience strengthens its position in the\nmarket. By connecting strategy, data, content, execution, and measurable\noutcomes, the company helps pharmaceutical organizations reduce fragmented\nhandoffs and improve commercialization efficiency. Its platform-agnostic\napproach allows customers to work in existing technology environments,\npreferred models, cloud relationships, security requirements, and governance\nstructures, reducing adoption friction while protecting existing technology\ninvestments.\n\nIts data-driven commercialization capabilities support precision marketing,\nnext-best-action journeys, healthcare professional targeting, field force\noptimization, channel selection, content frequency planning, and marketing\nspend optimization. By connecting digital engagement, field interaction,\ncustomer relationship management, claims, affinity, and prescribing signals,\nIndegene enables more intelligent omnichannel execution and more measurable\ncommercial decision-making.\n\nFrost & Sullivan commends Indegene for establishing a standard in competitive\nstrategy, technology-enabled execution, and market responsiveness. The\ncompany's domain-led approach to AI, knowledge orchestration capabilities, and\nfocus on transparent customer value are shaping the future of pharmaceutical\ncommercialization and enabling organizations to scale AI transformation with\ngreater confidence and accountability.\n\nEach year, Frost & Sullivan presents the Enabling Technology Leadership\nRecognition to a company that demonstrates outstanding strategy development\nand implementation, resulting in measurable improvements in customer value,\ncompetitive positioning, and market impact. The recognition highlights\nforward-thinking organizations that are reshaping their industries through\ninnovation and growth excellence.\n\nFor more details, read Frost & Sullivan's analysis of Indegene's capabilities.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=452544481&u=https%3A%2F%2Fwww.frost.com%2Fwp-content%2Fuploads%2F2026%2F10%2FIndegene_Writeup.pdf&a=Indegene%27s+capabilities.)\n\nFrost & Sullivan Best Practices Recognition\nFrost & Sullivan's Best Practices Recognitions honor companies across regional\nand global markets that exhibit exceptional achievement and consistent\nexcellence in areas such as leadership, technological innovation, customer\nexperience, and strategic product development. Each recognition is the result\nof a rigorous analytical process in which Frost & Sullivan industry experts\nbenchmark performance through comprehensive interviews, deep-dive analysis,\nand extensive secondary research. The goal is to identify true best-in-class\norganizations that are driving transformative growth and setting new industry\nstandards.\nContact us: Start the discussion\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4799011-1&h=2942711919&u=https%3A%2F%2Fww2.frost.com%2Fcontact-us%2F&a=Contact+us%3A+Start+the+discussion).\n\nContact:\nTarini Singh\nE: Tarini.Singh@frost.com \n\nAbout Indegene\nIndegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner\nto the life sciences industry, orchestrating commercial, medical, R&D, and\nsafety operations across the product lifecycle. Trusted by the world's top 20\nbiopharma companies, Indegene helps run complex, highly regulated workflows at\nglobal scale.\n\nIndegene combines deep life sciences expertise with AI-embedded platforms and\ngoverned operating models to improve speed, consistency, and compliance across\nmission-critical operations. By integrating technology into how work is\nexecuted and scaled, Indegene enables life sciences organizations to deliver\nmeasurable outcomes in regulated environments.\n\nFor more information, visit www.indegene.com.\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/indegene-receives-frost--sullivans-2026-global-enabling-technology-leadership-recognition-for-ai-powered-pharma-commercialization-302910484.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-22T05:30:00.691635791Z","server_sent_at_ms":1792647000691},"received_at":"2026-10-22T05:30:00.750Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}